MBX Biosciences (NASDAQ:MBX) Shares Gap Down – Here’s Why

MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $55.94, but opened at $53.28. MBX Biosciences shares last traded at $52.2280, with a volume of 19,149 shares traded.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. UBS Group reiterated a “buy” rating on shares of MBX Biosciences in a research note on Monday, September 28th. Weiss Ratings restated a “sell (d-)” rating on shares of MBX Biosciences in a research note on Thursday, October 15th. Truist Financial upped their target price on shares of MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a report on Monday, August 10th. Mizuho raised their target price on shares of MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, Barclays reiterated an “overweight” rating and set a $88.00 price target on shares of MBX Biosciences in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, MBX Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $87.30.

Get Our Latest Report on MBX Biosciences

MBX Biosciences Stock Up 0.6%

The stock’s 50 day moving average is $55.22 and its 200 day moving average is $46.64.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.49). Equities analysts forecast that MBX Biosciences, Inc. will post -3.40 earnings per share for the current year.

Insider Transactions at MBX Biosciences

In related news, CEO Steven Hoerter sold 4,893 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $54.82, for a total value of $268,234.26. Following the completion of the sale, the chief executive officer directly owned 78,045 shares in the company, valued at $4,278,426.90. The trade was a 5.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 31.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On MBX Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of MBX. Bank of America Corp DE bought a new position in MBX Biosciences during the second quarter worth about $16,501,000. The Manufacturers Life Insurance Company raised its stake in MBX Biosciences by 30.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 90,634 shares of the company’s stock worth $2,705,000 after purchasing an additional 21,083 shares in the last quarter. Elmind Capital LP bought a new stake in MBX Biosciences in the 2nd quarter valued at about $5,023,200. California State Teachers Retirement System boosted its holdings in MBX Biosciences by 1,197.9% in the 1st quarter. California State Teachers Retirement System now owns 22,765 shares of the company’s stock valued at $680,000 after purchasing an additional 21,011 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in MBX Biosciences in the 1st quarter valued at about $1,396,000.

About MBX Biosciences

(Get Free Report)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Featured Articles

Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.